TMCnet News
Immunoassay Instruments/Analyzers Market Forcasted To 2024 - Research and MarketsResearch and Markets has announced the addition of the "Immunoassay Instruments/Analyzers Market Revenue Analysis By Product (Chemiluminescence, Immunofluorescence Analyzers, Radioimmunoassay, Elisa), By Application (Oncology, Infectious Disease Testing, Autoimmune Disease), And Segment Forecasts To 2024" report to their offering. The global immunoassay instruments/analyzers market was valued at USD 14.7 billion in 2015 and is expected to reach a value of USD 23.3 billion by 2024. The prime factors driving the immunoassay analyzers market growth include constant introduction of advanced products. In addition, growing clinical applications for investigation and diagnosis of various chronic and related infectious diseases is expected to drive the growth of the immunoassay instruments market. The industry is rapidly growing due to the constant introduction and adoption of automated as well as advanced techniques for laboratory instruments and analyzers in developed countries. Rising prevalence of inectious diseases and chronic conditions, which require early diagnosis, prevention, and treatment, is one of the main factors boosting the demand for immunoassay analyzers and compact consumable products in the healthcare sector. In addition, industry is gaining speed with the launch of innovative products such as compact and portable ichroma II of Boditech Med, Inc., which is an FDA-approved fluorescence scanning instrument. Moreover, with the U.S. FDA approval of the iStat cardiac Troponin I test cartridge that uses enzyme-linked immunosorbant assay (ELISA) method, commercialization of such immunoassay products is also expected to increase significantly over the next few years. In North America, the government authorities and private companies have significantly contributed toward development of technology, supported research funding, and helped in commercialization of immunoassay analyzers and associated instruments. For instance, in June 2016, Abbott diagnostic launched Architect i1000SR, an automated immunoassay instrument that works on the principle of chemiluminescence. Using this system, number of different assays can be performed in a very short time. Key Topics Covered: 1 Research Methodology 2 Executive Summary 3 Market Variables, Trends& Scope 4 Market Categorization 1: Product Estimates & Trend Analysis 5 Market Categorization 3: Application Estimates & Trend Analysis 6 Market Categorization 4: Regional Estimates &Trend Analysis, by Product & Application type 7 Competitive Landscape For more information about this report visit http://www.researchandmarkets.com/research/lxnb5v/immunoassay View source version on businesswire.com: http://www.businesswire.com/news/home/20161230005181/en/ |
